Biochemical evaluation was performed on an Architect-ci8200 automated analyzer (Abbott Diagnostics, Abbott Park, Illinois) and included serum glucose, albumin, total cholesterol, high-density lipoprotein- (HDL-) cholesterol, low-density lipoprotein- (LDL-) cholesterol, triglycerides, total calcium, magnesium, and phosphorus. We used a specific chemiluminescent assay to measure PTH intact molecule (DiaSorin Inc., Stillwater, Minesota) with a sensitivity of 1 pg/mL, inter- and intra-assay coefficients of variation (CV) of 5.3% and 3.5%, respectively, and a normal reference range of 15-65 pg/mL). Serum 25 (OH) D3 was measured by means of a chemiluminescent assay (DiaSorin Inc., Stillwater, Minnesota) with a sensitivity of 4 ng/ml and inter- and intra-assay CVs of 5.1% and 8.6%, respectively.
Chemiluminescent assay
Manufactured by DiaSorin
Sourced in Italy
Chemiluminescent assay is a laboratory technique used to detect and quantify specific analytes in a sample. It utilizes a chemical reaction that produces light, which is then measured and correlated to the concentration of the target analyte.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using chemiluminescent assay
1
Biochemical Evaluation of Metabolic Markers
2
Klotho and FGF-23 in CKD Patients
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
A cross-sectional study was conducted in patients attending the Nephrology Department
of the Hospital das Clínicas of the São Paulo Medical School, FMUSP, from August
2016 to January 2017. Three groups of patients were included: 1) Control Group,
consisting of patients with hypertension, non-smokers and without CKD; 2) Patients
with CKD in stages III to IV (smokers and non-smokers); 3) Patients with CKD on
dialysis (smokers and non-smokers).
We included patients aged 18 to 70 years, in regular follow-up at the outpatient
clinic. Dialysis patients had been stable in the program for at least 6 months.
Patients with diabetes mellitus, neoplasia, lupus, serology positive for HIV virus,
as well as patients on immunosuppressants and corticosteroids were excluded. The
study was approved by the Research Ethics Committee of the Nove de Julho University
on June 4, 2016 (1,613,780).
We evaluated the patients' ages, genders, presence of comorbidities such as
hypertension and history of coronary and cerebrovascular disease, medications used
regularly and laboratory test results. Klotho dosages (IBL, Japan, sensitivity 6.15
pg/ml) were performed using enzyme-linked immunosorbent assay (ELISA), and those of
FGF-23 with chemiluminescent assay (Diasorin, Italy, sensitivity 5.0 pg/ml).
of the Hospital das Clínicas of the São Paulo Medical School, FMUSP, from August
2016 to January 2017. Three groups of patients were included: 1) Control Group,
consisting of patients with hypertension, non-smokers and without CKD; 2) Patients
with CKD in stages III to IV (smokers and non-smokers); 3) Patients with CKD on
dialysis (smokers and non-smokers).
We included patients aged 18 to 70 years, in regular follow-up at the outpatient
clinic. Dialysis patients had been stable in the program for at least 6 months.
Patients with diabetes mellitus, neoplasia, lupus, serology positive for HIV virus,
as well as patients on immunosuppressants and corticosteroids were excluded. The
study was approved by the Research Ethics Committee of the Nove de Julho University
on June 4, 2016 (1,613,780).
We evaluated the patients' ages, genders, presence of comorbidities such as
hypertension and history of coronary and cerebrovascular disease, medications used
regularly and laboratory test results. Klotho dosages (IBL, Japan, sensitivity 6.15
pg/ml) were performed using enzyme-linked immunosorbent assay (ELISA), and those of
FGF-23 with chemiluminescent assay (Diasorin, Italy, sensitivity 5.0 pg/ml).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!